Recently, Beijing CytoNiche Biotechnology Co., Ltd. (hereinafter referred to as "CytoNiche") and Seiko Trading Shanghai Co., Ltd. (hereinafter referred to as "Seiko Trading") have developed a strategic partnership on the marketing of all CytoNiche's products and services in eastern China and overseas markets.

Seiko Group, the parent company of Seiko Trading Shanghai Co., Ltd. is one of the largest healthcare research service providers in Japan. With 70 years of professional experience in healthcare research and a strong platform, Seiko Trading has been serving professional customers of various specialties engaged in research and development and especially that of healthcare in China all year round. Seiko Trading has established long-term cooperative relations with famous brands in Europe, America, Japan and China. Seiko provides suitable products in time according to customer's needs, as well as various types of after-sales service. By making good use of the knowledge accumulated over the years and the good relationships maintained with manufacturers, Seiko Trading has a stable customer sales and service network, and provides customers from all walks of life with rich information resources.

CytoNiche is committed to building a self-developed smart manufacturing platform for 3D cell culture. The company developed 3D FloTrix®, an automated cell preparation system based on 3D microcarrier culture technique. It provides a systematic solution to customized, large-scale cell culture, and serves industries related to stem cell, vaccine, gene therapy, immunotherapy, etc. It has helped a number of enterprises establish fully closed automated cellular drug production lines, realizing the mass production of cellular drugs and their by-products by adopting an automated, standardized and smart production process. This has sped up the research on stem cells applications and the development of new drugs, helping turn innovative findings into commercialized products or making such findings enter the clinical trial stage faster.

Based on mutual trust and mutual benefit, the two parties have drawn on each other’s strengths to combine their resources, serve customers at home and abroad, accelerate business expansion and promote the development of the cell culture industry.

【Win-Win Cooperation】

Mr. Sun Chengliang, General Manager of Seiko Trading, Mr. Cheng Gaofeng, Director of Sales Department of Seiko Trading, Dr. Liu Wei, General Manager of CytoNiche, Mr. Wang Zhiqian, Director of Marketing Center of CytoNiche, and Mr. Han Chunzhou, Sales Director for Eastern China of CytoNiche, amongst other representatives from the two parties attended the signing ceremony.

【About Seiko Trading】

Seiko Trading Shanghai Co., Ltd. is a wholly-owned subsidiary of Seiko Group, one of the largest healthcare research service providers in Japan founded in 1950. It is engaged in a wide range of businesses including the sales, marketing and other services related to in vitro diagnostic reagents, diagnostic reagent raw materials and all-round research solutions.

Seiko Trading studies and judges future industry trends wisely, carefully selects products of brands from Europe, America, Japan and China, and practices the business concept of "honesty, integrity and precision" in every stage of the company's development. With its operation team's insight into the industry, Seiko Trading demonstrates strong professional capabilities and strives to lead the industry in comprehensive professional service. Today, Seiko Trading has established long-term partnerships with more than 3500 clients and their total sales revenue has exceeded 400 million yuan.

While keeping up with the times and relying on the powerful resource of Seiko Group, Seiko Trading has formulated a development strategy featuring resource integration that meets the needs of different clients to provide higher added values for the society. Seiko Trading makes innovation with a progressive, pragmatic work attitude, and strives to make Seiko a century-old brand.

【About CytoNiche】

Beijing CytoNiche Biotechnology Co., Ltd. was established by the research team of Professor Du Yanan from Tsinghua University School of Medicine, and was jointly established by Tsinghua University through equity participation. The core technologies were derived from the transformation of scientific and technological achievements of Tsinghua University. CytoNiche focuses on building an original 3D cell "smart manufacturing" platform, as well as providing overall solutions for the 3D microcarrier-based customized cell amplification process.

CytoNiche's core product, 3D TableTrix® Microcarrier Tablet (Microcarrier), is an independent innovation and the first pharmaceutical excipient grade microcarrier that can be used for cell drug development. It has obtained the certificate of analysis from relevant authoritative institutions such as National Institutes for Food and Drug Control, and obtained 2 qualifications for pharmaceutical excipients from the National Medical Products Administration (CDE approval registration number: F20210000003, F20210000496). Moreover, the product has obtained the DMF qualification for pharmaceutical excipients from U.S. FDA (DMF: 35481). 

Products and services of CytoNiche can be widely used in the upstream process development of gene and cell therapy, extracellular vesicles, vaccines, and protein products. At the same time, it also has broad prospects for applications in the fields of regenerative medicine, organoids, and food technology (cell-cultured meat, etc.).

Our company has a R&D and transformation platform of 5,000 square meters, including a CDMO platform of more than 1,000 square meters, a GMP production platform of 4,000 square meters, and a new 1200 L microcarrier production line. The relevant technologies have obtained more than 100 patents and more than 30 articles about the technologies in international journals have been published. The core technology projects have obtained a number of national-level project support and applications.